EUVIMEDEUVIMED entdecken
ValidierungsstudieKohortenstudieOpen Access

Development and Validation of an Extra Spindle Pole Bodies–like 1–Based Diagnostic and Prognostic Model for Hepatitis B Virus–Related Hepatocellular Carcinoma: Retrospective Cohort Study

Lu-Huai Feng iD, Hengkai Liang iD, Bobin Hu iD, Lu Wei iD, Qingmei Li iD, Tumei Su iD, Qianbing Yin iD, Yanfei Feng iD, Long Huang iD, Hongqian Liang iD, Minghua Su iD, Jianning Jiang iD

JMIR Medical Informatics · 2025

DOI: 10.2196/78354 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift JMIR Medical Informatics, 2025. Verfasst von Lu-Huai Feng und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, China, 86 0771-57…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis B, Chronic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early diagnosis of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) is challenging. Models that combine novel biomarkers with clinical features may improve both early diagnosis and risk stratification, but few have been systematically validated.

Objective

This study aimed to develop and validate an extra spindle pole bodies–like 1 (ESPL1)–based model for diagnostic discrimination of HBV-related HCC and longitudinal risk stratification in patients with chronic HBV infection.

Methods

Patients with chronic HBV were consecutively recruited from the First Affiliated Hospital of Guangxi Medical University (a single-center, tertiary hospital) between January 2012 and November 2023. Patients were divided into a training set and an independent hold-out testing set. A LASSO logistic regression model was constructed to identify independent predictors and then used to develop a risk score discriminating patients with HBV-related HCC from those with chronic hepatitis B or cirrhosis. Model performance was evaluated using discrimination (C-index), calibration, and decision curve analysis. Internal validation was performed with bootstrap resampling, and independent hold-out validation was conducted with the independent hold-out testing set. Longitudinal follow-up of patients with chronic hepatitis B or cirrhosis was subsequently used to examine cumulative incidence across risk groups, thereby assessing the model’s ability to stratify future HBV-related HCC risk. A web-based calculator was developed to facilitate clinical application.

Results

The study involved a cohort of 621 patients diagnosed with chronic HBV infection, divided into a training set of 373 (60.1%) patients and an independent hold-out testing set of 248 (39.9%) patients. Age (odds ratio [OR] 1.08, 95% CI 1.05‐1.12), ESPL1 expression (OR 1.01, 95% CI 1.00‐1.01), and log (alpha-fetoprotein) levels (OR 2.55, 95% CI 1.95‐3.33) were identified as independent predictors of HBV-related HCC. The model demonstrated excellent diagnostic discrimination, with a C-index of 0.922 in the training set and 0.958 in the independent hold-out testing set, coupled with strong calibration. Decision curve analysis revealed that the model consistently provided a higher net benefit across clinically relevant threshold probabilities. Subgroup analyses further validated the model’s high discriminative power, with C-index values ranging from 0.86 to 0.98, and no significant interactions were detected (all interaction P values > .10). Furthermore, the model demonstrated superior discriminatory power relative to 5 established HBV-related HCC risk scores, including REACH-B, GAG-HCC, CU-HCC, PAGE-B, mPAGE-B, and alpha-fetoprotein alone, with all pairwise comparisons yielding statistical significance ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis B, ChronicHumansMaleFemaleRetrospective StudiesMiddle AgedPrognosisHepatitis B virusAdultBiomarkers, Tumor

Stichwörter der Autor:innen

ESPL1alpha-fetoproteinhepatocellular carcinomamachine learningweb calculator

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, China, 86 0771-5719573.
  • Key Laboratory of Early Prevention and Treatment of Regional High Incidence Tumors (Guangxi Medical University), Ministry of Education, Nanning, China.
  • Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Nanning, China.

ORCID-Profile: Lu-Huai Feng, Hengkai Liang, Bobin Hu, Lu Wei, Qingmei Li, Tumei Su, Qianbing Yin, Yanfei Feng, Long Huang, Hongqian Liang, Minghua Su, Jianning Jiang

Zitieren

APA

Feng, L. H., Liang, H., Hu, B., Wei, L., Li, Q., Su, T., Yin, Q., Feng, Y., Huang, L., Liang, H., Su, M., & Jiang, J. (2025). Development and Validation of an Extra Spindle Pole Bodies–like 1–Based Diagnostic and Prognostic Model for Hepatitis B Virus–Related Hepatocellular Carcinoma: Retrospective Cohort Study. JMIR Medical Informatics. https://doi.org/10.2196/78354

Vancouver

Feng LH, Liang H, Hu B, Wei L, Li Q, Su T, et al. Development and Validation of an Extra Spindle Pole Bodies–like 1–Based Diagnostic and Prognostic Model for Hepatitis B Virus–Related Hepatocellular Carcinoma: Retrospective Cohort Study. JMIR Medical Informatics. 2025. doi:10.2196/78354

BibTeX
@article{Feng2025,
  author = {Feng, Lu-Huai and Liang, Hengkai and Hu, Bobin and Wei, Lu and Li, Qingmei and Su, Tumei and Yin, Qianbing and Feng, Yanfei and Huang, Long and Liang, Hongqian and Su, Minghua and Jiang, Jianning},
  title = {Development and Validation of an Extra Spindle Pole Bodies–like 1–Based Diagnostic and Prognostic Model for Hepatitis B Virus–Related Hepatocellular Carcinoma: Retrospective Cohort Study},
  journal = {JMIR Medical Informatics},
  year = {2025},
  doi = {10.2196/78354}
}
Kostenlos starten →